Phase I dose escalation of paclitaxel in patients with advanced ovarian cancer receiving cisplatin: rapid development of neurotoxicity is dose-limiting.
Authors:
- C A StringerCSC A Stringer
- C M MatthewsCMC M Matthews
- D L WillisDWD L Willis
- J NemunaitisJNJ Nemunaitis
- 1 May 1997
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 15 (5) , 1965-1973